Answers are grounded in this paper and cite their sources.
"Liquid biopsy" was introduced as a new diagnostic concept in 2010 for the analysis of circulating tumor cells (CTCs) and has been now extended to material (in particular DNA) released by tumor cells in the peripheral blood of cancer patients. Over the past decade, various methods have been developed to detect CTCs and ctDNA in the peripheral blood of cancer patients.
No takes yet. Share an insight, caveat, or question.
Reimers et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: